Tefinostat
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tefinostat
- DrugBank Accession Number
- DB15321
- Background
Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 495.62
Monoisotopic: 495.273321303 - Chemical Formula
- C28H37N3O5
- Synonyms
- Tefinostat
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Tefinostat is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Tefinostat is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Tefinostat is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Tefinostat is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Tefinostat is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- ZAU91150SB
- CAS number
- 914382-60-8
- InChI Key
- GLNWREBYRLDPQP-MHZLTWQESA-N
- InChI
- InChI=1S/C28H37N3O5/c32-25(14-6-1-2-7-15-26(33)31-35)30-23-18-16-21(17-19-23)20-29-27(22-10-4-3-5-11-22)28(34)36-24-12-8-9-13-24/h3-5,10-11,16-19,24,27,29,35H,1-2,6-9,12-15,20H2,(H,30,32)(H,31,33)/t27-/m0/s1
- IUPAC Name
- cyclopentyl (2S)-2-[({4-[7-(hydroxycarbamoyl)heptanamido]phenyl}methyl)amino]-2-phenylacetate
- SMILES
- ONC(=O)CCCCCCC(=O)NC1=CC=C(CN[C@H](C(=O)OC2CCCC2)C2=CC=CC=C2)C=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 13083627
- ZINC
- ZINC000034775091
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 1, 2 Unknown Status Treatment Hepatocellular Carcinoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0012 mg/mL ALOGPS logP 3.91 ALOGPS logP 4.48 Chemaxon logS -5.6 ALOGPS pKa (Strongest Acidic) 8.91 Chemaxon pKa (Strongest Basic) 4.71 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 116.76 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 138.68 m3·mol-1 Chemaxon Polarizability 55.59 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-002b-0006900000-fd1c70dd9608a7dbc1ff Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0bta-0001900000-15bd04bac55c2315f08b Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-05mp-3009500000-0db9d20933dc72265974 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0uxr-0019200000-c8e4b48500fc9a54b427 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-11vs-1129200000-cffd66dfb57b74bbfedc Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0ka6-9037400000-c6ee159a3ac21fa85266 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 269.0350179 predictedDarkChem Lite v0.1.0 [M+H]+ 269.4887179 predictedDarkChem Lite v0.1.0 [M+Na]+ 268.3742179 predictedDarkChem Lite v0.1.0
Drug created at May 20, 2019 15:14 / Updated at February 21, 2021 18:55